The Effect of Vitamin C on Pathological Parameters and Survival Duration of Critically Ill Coronavirus Disease 2019 Patients: A Randomized Clinical Trial중환자 코로나바이러스 질환 2019 환자의 병리학적 매개변수 및 생존 기간에 대한 비타민 C의 영향: 무작위 임상 시험Randomized Controlled Trial Published on 2021-12-152022-09-11 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 임상, [키워드] ABG albumin arterial blood arterial blood gas arterial pressure association baseline biochemical parameter Biochemical parameters Blood blood count blood gas blood glucose calcium CBC Cell clinical clinical trial Coma conducted control group coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill Critically ill patient critically ill patients demonstrated Duration Effect except for Glasgow coma scale Glucose had no hematocrit hemoglobin Hospitalized Ill infected with COVID-19 Intervention intervention group Kidney function linear mean arterial pressure measurement no effect parameter parameters partial thromboplastin time pathological Patient phosphorus Platelet Plt Potassium Registration reported Result scale serum serum electrolyte significantly lower sodium Supplementation survival the patient THROMBOPLASTIN Vitamin Vitamin C was performed with COVID-19 [DOI] 10.3389/fimmu.2021.717816 PMC 바로가기 [Article Type] Randomized Controlled Trial
Impact of Coinfection With SARS-CoV-2 and Influenza on Disease Severity: A Systematic Review and Meta-AnalysisSARS-CoV-2 및 인플루엔자와의 동시 감염이 질병 중증도에 미치는 영향: 체계적인 검토 및 메타 분석Review Published on 2021-12-102022-09-11 Journal: Frontiers in Public Health [Category] SARS, 치료기술, [키워드] aPTT article association calculate China CNKI Cochrane Library Coinfection COVID-19 patient COVID-19 patients Critical disease disease severity Effect evaluate fixed had no identify Impact indicated Infection influence Influenza influenza strain influenza vaccination Infrastructure Laboratory lower risk lymphocyte Lymphocyte count lymphocyte counts material Meta-analysis Mortality no effect outcome overall mortality Patient random effect Region Result review risk risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection searched significantly significantly increased simultaneously infected the disease vaccination virus viruses Web of Science [DOI] 10.3389/fpubh.2021.773130 PMC 바로가기 [Article Type] Review
Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19COVID-19 환자의 사이토카인 방출 증후군에 대한 클로로퀸 및 하이드록시클로로퀸의 효과Randomized Controlled Trial Published on 2021-12-012022-09-11 Journal: Clinical medicine & research [Category] SARS, 임상, 치료기술, 치료제, [키워드] Adult patients age blinded Care Chain Reaction Chloroquine conducted coronavirus disease Coronavirus disease 2019 COVID-19 CRS Cytokine release syndrome Department diagnose diagnoses Effect electrochemiluminescence immunoassay Emirate enrolled hospitalized patient Hydroxychloroquine IL-6 interleukin interleukin 6 Medicine Mild mild to moderate mild to moderate symptoms moderate no effect no significant difference onset of symptom Patient patients patients with COVID-19 placebo-controlled polymerase chain polymerase chain reaction randomization randomized study reducing Release Result reverse transcription reverse transcription polymerase chain reaction Roche RT-PCR screened serum sample serum samples significant difference study groups Symptoms the mean the patient three groups Treatment with COVID-19 [DOI] 10.3121/cmr.2021.1659 PMC 바로가기 [Article Type] Randomized Controlled Trial
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9COVID-19 후 지속적인 폐 병리학은 높은 바이러스 부하, 약한 항체 반응 및 높은 수준의 매트릭스 메탈 로프 로테네 아제 -9와 관련이 있습니다.Randomized Controlled Trial Published on 2021-12-012022-09-01 Journal: Scientific Reports [Category] SARS, 바이오마커, 임상, 진단, 치료법, 치료제, [키워드] Admission antibody Antibody Response Antimicrobial responses association clinical trial COPD COVID-19 diffusion capacity disease severity Efficacy except for Ground-glass opacities HCQ high viral load hospital Hospital admission hospitalisation Hydroxychloroquine ICU treatment limit lung Lungs marker matrix metalloproteinase mediators no effect outcome outcomes parenchymal Patient performed persistent Predictive markers predictor Prevalence pro-fibrotic Pulmonary pathology randomised reduced Remdesivir respiratory Respiratory distress syndrome respiratory symptoms spirometry Trial Viral viral infection Viral load [DOI] 10.1038/s41598-021-02547-x PMC 바로가기 [Article Type] Randomized Controlled Trial
Host-modifying drugs against COVID-19: some successes, but not yet the breakthroughCOVID-19에 대한 숙주 변형 약물: 일부 성공, 그러나 아직 돌파구 없음Review Published on 2021-12-012022-09-11 Journal: Environmental microbiology [Category] meta-analysis, SARS, 임상, 치료제, [키워드] Anakinra anti-inflammatory treatment antibiotic anticoagulation antiviral drug antiviral drugs Azithromycin Baricitinib benefit clinical clinical benefit clinical benefits clinical trial clinical trials Colchicine Corticosteroid COVID-19 patients criteria demonstrated Dexamethasone drug Effect hospitalized patient hospitalized patients hyperinflammation immunomodulators immunomodulatory activity Infection inferiority inhibitor interleukin 6 interleukin 6 receptor Janus kinase Kinase inhibitor Meta-analysis Microbiology Mortality no effect no effects outcome oxygen pathology Patient receptor receptor antagonist reducing Repurposed drug Repurposed drugs SARS-CoV-2 virus severe cases stages subgroups of patient supplementary oxygen survival the SARS-CoV-2 virus therapeutic dose Tocilizumab Treatment Trial Ventilation [DOI] 10.1111/1462-2920.15828 PMC 바로가기 [Article Type] Review
Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies전신 자가면역 질환에서 항 SARS-CoV-2 mRNA 백신의 효능: 높은 결합력 유도 및 항-RBD 항체 중화Article Published on 2021-12-012022-09-11 Journal: RMD Open [Category] SARS, 진단, 치료기술, [키워드] abatacept ACE2 Anti-RBD antibodies Anti-RBD antibody Anti-RBD IgG anti-SARS-CoV-2 antibodies Antibody avidity Autoimmune Autoimmune diseases boost control group controls COVID-19 detectable disorder domain elicited ELISA evaluate evaluated first dose healthcare worker healthy control healthy controls IgA IgA antibodies IgA antibody IgG IgG antibodies IgG antibody IgM immune response inhibiting Interaction mRNA vaccine mycophenolate neutralising Neutralising activity Neutralising Antibodies no effect not significantly different Patient patients produced RBD RBD IgG SARS-CoV-2 the patient therapy These data titre urea vaccination was tested were measured [DOI] 10.1136/rmdopen-2021-001914 PMC 바로가기 [Article Type] Article
Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine비활성화된 SARS-CoV-2 백신에 대한 인간 IgM 및 IgG 반응Article Published on 2021-12-012022-09-11 Journal: Current medical science [Category] MERS, SARS, 진단, 치료기술, [키워드] accelerated age All participant All participants all subjects anti-IgG antibody Antibody Response Antibody responses COVID-19 COVID-19 pandemic defined dose dose of vaccination Effects effort elicited Factor female for inclusion had no healthy individuals Human IgG antibodies IgG antibody IgM IgM and IgG IgM and IgG antibody responses in healthy individual inactivated inactivated SARS-CoV-2 vaccine. individual less male no effect Older positive result recipients response Retrospective study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine second dose seropositive significantly higher significantly lower subject vaccination vaccine candidates were assessed [DOI] 10.1007/s11596-021-2461-8 PMC 바로가기 [Article Type] Article
Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study코로나바이러스 질병 2019에서 저분자량 헤파린 사용은 바이러스 지속성 감소와 관련이 있습니다: 후향적 다기관 관찰 연구Observational Study Published on 2021-12-012022-09-10 Journal: Cardiovascular Research [Category] SARS, 바이오마커, 임상, [키워드] (cfDNA) 95% confidence interval anticoagulation attenuation Biomarker cell death cell-free DNA cfDNA Chain Reaction Coagulopathy contraindications coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 patient COVID-19-associated coagulopathy D-dimer decrease different time point different time points Effect evaluate evaluated haemostasis hazard ratio heparin Hospitalization Hospitalized hospitalized COVID-19 patient hypercoagulability interquartile interquartile range LMWH Low-molecular-weight heparin marker mechanism Mortality multicentre multivariable Cox regression no effect NOAC oral anticoagulant outcome Patient patients with COVID-19 plasma polymerase chain polymerase chain reaction Quantitative quantitative polymerase chain reaction reduced reduction Region responsible retrospective SARS-CoV-2 viral persistence subset survival the cell Thromboinflammation time Viral viral persistence virus was collected [DOI] 10.1093/cvr/cvab308 PMC 바로가기 [Article Type] Observational Study
Case study: risk associated to wearing silver or graphene nanoparticle-coated facemasks for protection against COVID-19사례 연구 : COVID-19로부터 보호하기 위해은 또는 그래 핀 나노 입자 코팅 된 페이스 마스크를 착용하는 것과 관련된 위험Nanotoxicology Published on 2021-11-162022-09-10 Journal: Archives of Toxicology [Category] MERS, SARS, 치료기술, 치료제, [키워드] addition approach Chronic exposure coating COVID-19 database derivation effective exposure to facemask facemasks genotoxicity Grapheme Graphene Infection mandatory no effect pandemic Prevent prophylactic measure prophylactic measures repeated risk Risk assessment Safe SARS-CoV-2 virus silver silver nanoparticle Silver nanoparticles toxicokinetics [DOI] 10.1007/s00204-021-03187-w PMC 바로가기 [Article Type] Nanotoxicology
ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patientsLetter to the Editor Published on 2021-11-112022-10-29 Journal: Journal of Cellular and Molecular Medicine [Category] COVID-19, [키워드] ACEi administration alleviate Ang II ARB attenuate benefit blockers Clinical outcome conditions coronavirus disease COVID‐19 COVID‐19 patient COVID‐19 patients COVID‐19 enzyme exhibit Guidance hypertension hypertensive IMPROVE Infection inflammatory reaction lower risk Lung fibrosis mechanical ventilation Mortality no effect offer Patient Prognosis question receiving receptor retrospective severe ARDS Severe patient significantly Treatment [DOI] 10.1111/jcmm.17051 PMC 바로가기 [Article Type] Letter to the Editor